Olopatadine
Summary
Persistence.The potential for persistence of olopatadine cannot be excluded, due to lack of data.
Bioaccumulation. Olopatadine has low potential for bioaccumulation.
Toxicity. It cannot be excluded that olopatadine is toxic, due to lack of data.
Risk. Risk of environmental impact of olopatadine cannot be excluded, since no ecotoxicity data are available.
This summary information comes from fass.se for Opatanol (olopatadine).
Detailed information
Fass environmental information
Fass environmental information for Opatanol (olopatadine) from Novartis Sverige AB (retrieved on 2026-02-19).
Metabolism
Following topical ocular administration, olopatadine has a plasma elimination half‑life of about 3 hours. The drug undergoes limited metabolism; after oral administration, unchanged olopatadine accounts for 77% of total plasma radioactivity, while metabolites represent less than 6%. The plasma elimination half‑life after oral dosing is 8–12 hours. Olopatadine is primarily eliminated renally, with 60–70% of the absorbed dose excreted in urine (86% as unchanged drug), and about 17% excreted in feces.
Hazard
Persistence: No data.
Bioaccumulation: Log Kow = 0.342 (method unknown).
Toxicity: No data.
Risk
PEC is based on sales data in Sweden in year 2021.
PEC = 0.0001 microg/L.
Risk of environmental impact of olopatadine cannot be excluded, since no ecotoxicity data are available.
References
Author: Health and Medical Care Administration, Region Stockholm